Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

(2021) Stephanie Lheureux et al.   LANCET

Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer

(2021) Peter Q. Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cyclin E in normal physiology and disease states

(2021) Chen Chu et al.   TRENDS IN CELL BIOLOGY

Structural conservation of WEE1 and its role in cell cycle regulation in plants

(2021) A. Détain et al.   Scientific Reports

Checkpoint Responses to DNA Double-Strand Breaks

(2020) David P. Waterman et al.   Annual Review of Biochemistry

601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours

(2020) H. Gelderblom et al.   ANNALS OF ONCOLOGY

A kinetochore-based ATM/ATR-independent DNA damage checkpoint maintains genomic integrity in trypanosomes

(2019) Qing Zhou et al.   NUCLEIC ACIDS RESEARCH

O-GlcNAcylation of Thr12/Ser56 in short-form O-GlcNAc transferase (sOGT) regulates its substrate selectivity

(2019) Li Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mutant p53 as a guardian of the cancer cell

(2018) Fiamma Mantovani et al.   CELL DEATH AND DIFFERENTIATION

Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors

(2017) Jin-Yi Zhu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Orchestration of DNA Damage Checkpoint Dynamics across the Human Cell Cycle

(2017) Hui Xiao Chao et al.   Cell Systems

Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

(2017) J. H. M. Schellens et al.   JOURNAL OF CLINICAL ONCOLOGY

Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway

(2016) Stephanie A. Yazinski et al.   Annual Review of Genetics

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

(2016) Suzanne Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword

(2016) Roberta Visconti et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy

(2016) V Clausse et al.   Cell Death & Disease

The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy

(2015) Michael Goldstein et al.   Annual Review of Medicine

The same, only different - DNA damage checkpoints and their reversal throughout the cell cycle

(2015) I. A. Shaltiel et al.   JOURNAL OF CELL SCIENCE

PP2ARts1is a master regulator of pathways that control cell size

(2014) Jessica Zapata et al.   JOURNAL OF CELL BIOLOGY

Wee1 kinase as a target for cancer therapy

(2013) Khanh Do et al.   CELL CYCLE

Checkpoint kinase 1 in DNA damage response and cell cycle regulation

(2013) Mallikarjun Patil et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Targeting Wee1 for the treatment of pediatric high-grade gliomas

(2013) Sabine Mueller et al.   NEURO-ONCOLOGY

Chk1 and Wee1 kinases coordinate DNA replication, chromosome condensation, and anaphase entry

(2012) Barbara Fasulo et al.   MOLECULAR BIOLOGY OF THE CELL

H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes

(2012) Kiran Mahajan et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy

(2012) Gry Irene Magnussen et al.   PLoS One

p21WAF1is component of a positive feedback loop that maintains the p53 transcriptional program

(2011) Lisa Y. Pang et al.   CELL CYCLE

Targeting the S and G2 checkpoint to treat cancer

(2011) Tao Chen et al.   DRUG DISCOVERY TODAY

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

(2010) Shahryar E. Mir et al.   CANCER CELL

Gambogic acid triggers DNA damage signaling that induces p53/p21Waf1/CIP1 activation through the ATR-Chk1 pathway

(2010) Jing-Jing Rong et al.   CANCER LETTERS

A Mitotic Phosphorylation Feedback Network Connects Cdk1, Plk1, 53BP1, and Chk2 to Inactivate the G2/M DNA Damage Checkpoint

(2010) Marcel A. T. M. van Vugt et al.   PLOS BIOLOGY

Fine Tuning the Cell Cycle: Activation of the Cdk1 Inhibitory Phosphorylation Pathway during Mitotic Exit

(2009) Tamara A. Potapova et al.   MOLECULAR BIOLOGY OF THE CELL

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

(2009) Shinji Mizuarai et al.   Molecular Cancer

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets

(2009) Elizabeth Iorns et al.   PLoS One

Conserved functions of the pRB and E2F families

(2008) Sander van den Heuvel et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Regulation of DNA repair throughout the cell cycle

(2008) Dana Branzei et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY